Lexeo Therapeutics to host investor event on clinical endpoints in PKP2-ACM

LXEO•2026-10-19

Lexeo Therapeutics will host an educational investor event on PKP2 arrhythmogenic cardiomyopathy on Oct. 21, 2026, at 1 p.m. ET, focused on clinical assessments of arrhythmias used to evaluate disease burden and treatment response.

1. Investor event details

Lexeo Therapeutics will host an educational investor event on PKP2 arrhythmogenic cardiomyopathy on Oct. 21, 2026, at 1 p.m. ET. Speakers will include Chief Medical Officer Narinder Bhalla and Cleveland Clinic physician-scientist Alessio Gasperetti.

Lexeo Therapeutics to host investor event on clinical endpoints in PKP2-ACM

1. Investor event details

Related News

Raymond James cuts Oceanagold target price to C$52 from C$53

Golar LNG announces Q3 results presentation

Jefferies raises Coty target price to $2.95 from $2.4

Wynn Resorts target price cut to $120 from $128

CME Group expands dairy business with new European futures and options